Track China Pharma Holdings, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

China Pharma Holdings, Inc. CPHI · Stock Open China Pharma Holdings, Inc. in new tab

0.6951 USD
EPS
-0.54
P/B
0.53
ROE
-16.12
Beta
1.00
Loading chart...
Key Metrics
Earnings dateMay 15, 2026
EPS-0.54
Book Value1.47
Price to Book0.53
Debt/Equity9.61
% Insiders98.024%
Growth
Revenue Growth-0.13%

DCF Valuation

Tweak assumptions to recompute fair value for China Pharma Holdings, Inc. (CPHI)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

China Pharma Holdings, Inc. Logo China Pharma Holdings, Inc. Analysis (CPHI)

China Health Care Official Website Stock

Is China Pharma Holdings, Inc. a good investment? China Pharma Holdings, Inc. (CPHI) is currently trading at 0.6951 USD.

Earnings Schedule: China Pharma Holdings, Inc. is expected to release its next earnings report on May 15, 2026.

Investor FAQ

Does China Pharma Holdings, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is China Pharma Holdings, Inc.?

China Pharma Holdings, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 15, 2026. The company currently has a trailing EPS of -0.54.

Company Profile

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.

Exchange Ticker
ASE (United States) CPHI
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Aug. 15, 2003 0.050000
March 6, 2023 0.100000
March 6, 2024 0.200000
April 15, 2025 0.100000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion